into DNA that expressed c-myc mRNA. In addition, one clone with an integrated neo gene but a deleted c-myc gene was isolated and in this case c-myc was not expressed. C-myc expression in transfected clones was associated with altered large cell morphology, a shorter doubling time, and increased cloning efficiency, but no difference in L dopa decarboxylase levels and bombesinlike immunoreactivity. We conclude increased c-myc expression observed here in transfected clones correlates with some of the phenotypic properties distinguishing c-myc amplified variants from unamplified classic small cell lung cancer lines.
Introduction
Some previously identified biologic activities of the c-myc gene in mammalian cells include the ability to immortalize rat fibroblast cells (1) and to cooperate with ras-like oncogenes to induce tumorigenic conversion of primary rat embryo fibroblast cells (2) . In addition, c-myc gene expression appears to stimulate transfected rat fibroblasts to form tumors in nude mice and syngeneic rats (3) and is associated with breast cancer in transgenic mice (4) . Further, c-myc expression is induced by a wide variety of mitogens including serum (5) , platelet derived growth factor, fibroblast growth factor (FGF), epidermal growth factor (EGF) (6) (7) (8) , and partial hepatectomy (9, 10) . Increased c-myc expression in transfected cell lines is also associated with a higher cloning efficiency in soft agar and a more rapid growth rate of rat fibroblast cells in low serum conditions (1, 3) .
Small cell lung cancer (SCLC)' cells offer another opportunity for studying the biologic role of c-myc. The variant subset of SCLC cell lines has a four-to 60-fold DNA amplification of cmyc and shows high expression ofthis gene (1 1, 12) . In addition, a large amount ofimmunoreactive c-myc protein has been demonstrated in a c-myc amplified variant SCLC cell line, N417 (13) . Compared with the more common classic SCLC lines, which do not express c-myc, variant cell lines have altered morphology in cell culture (growth in loose chains), altered athymic nude mouse xenotransplant histology (large cells with abundant cytoplasm and prominent nucleoli), and different biochemical properties from classic SCLC. The variants produce low or undetectable levels of L dopa decarboxylase, a marker of neuroendocrine differentiation. They also produce low or undetectable levels of bombesin-like immunoreactivity (gastrin releasing peptide), a putative autocrine growth factor in small cell lung cancer ( 14) . The SCLC variants also have a more rapid doubling time, a 10-fold higher soft agarose cloning efficiency, and are less radiosensitive (15) (16) (17) . Thus, the two types of cell lines derived from different patients with the same malignancy have easily evaluable phenotypic differences and the more aggressive variant phenotype is closely associated with c-myc amplification and expression.
Although a close association with the more aggressive variant phenotype of SCLC cell lines has been demonstrated, the causal role for c-myc in generating the variant phenotypic has not been proven. The recent development of electroporation (18) (19) (20) for introducing DNA into cells growing in suspension has allowed us to introduce a normal human c-myc gene covalently linked to the neomycin resistance gene, aminoglycoside 3' phosphotransferase (neo), into a classic SCLC cell line. Transformants expressing the transfected DNA can then be selected using the aminoglycoside antibiotic G-4 18. Thus, we are able to ask if cmyc could be expressed and affect the phenotype of a classic SCLC cell line and compare the transformants to amplified variant SCLC cell lines. amounts ofc-myc mRNA. The cell line H209 was cloned in soft agarose and one of the clones, DD1, was used for the electroporation. The cells were grown under standard conditions (15, 16 This plasmid was linearized with Pvu I and electroporated with 5 X 106 cells from cloned cell line H209 DDI at 2 KV at 00C (18) . After electroporation, the cells were resuspended at 1 X 106 cells/ml in 10% fetal calf serum (FCS)-RPMI 1640 for 1 wk, and were then selected at 800 pg/ml ofG-418 (real concentration, 370 Ag/ml). 5 X 104 cells were placed in each well of a 96-well microtiter dish and 35 clones were isolated.
Preparation ofDNA and RNA. Cells were grown to a density of 2-5 X 106 cells/ml in log phase culture. Total cellular RNA and DNA was prepared from the same cells as described by Chirgwin (21) and Hieter (22) .
Southern, Northern, and S nuclease analysis. Southern blots were prepared, hybridized, washed, and exposed as described by Southern (23) and Little (1 1) . Northern blots were prepared, hybridized, washed, and exposed on radiographs as described by Little (1 1). The DNA restriction fragments labeled by nick translation were an Rsa l-Xba I fragment containing the first exon (first exon probe), an Eco RI-Cla I fragment containing the third exon (third exon probe), and a Bam HIBam HI fragment containing the neomycin gene (neo probe). The same Northern blot was washed at 70°C and rehybridized to a human beta actin probe to control for the amount ofmRNA (24) . SI nuclease studies were carried out as described by Battey (25 (26, 27) .
Cell culture morphology and nude mouse histology. The cell culture photographs were taken of cell lines and transfected clones growing in log phase growth in 10% FCS-RPMI 1640 The parental cell line, H209, and all five transfected clones retain the 11.4-kb Hind III germ line c-myc fragment (Fig. 3,  panel 2 ). In addition, clones A, B, C, and E have new bands at 8.8 kb, the predicted size of a Hind III c-myc fragment from the c-myc-neo construct (Fig. 1) . Clone D is missing this novel sized Hind III band despite the presence ofa neogene (Fig. 2) . Parental H209 and all five clones show the germ line 23-kb Bam HI fiagment containing the third exon of c-myc (Fig. 3, panel 3 ).
In addition, clones A, B, C, and E show differently sized bands. The Bam HI cleaves once in the c-myc-neo construct at the 5' origin of the neo gene and once at the next flanking genomic Bam HI site 5' to the integrated portion of c-myc-neo construct. Clone D again shows no evidence of a novel third exon hybridizing fragment from the c-myc-neo construct. The germ line 14.7 kb Sst I fragment containing the first exon is seen in the H209 parental cell line and all five clones (Fig. 3, panel 4) . In Expression oftransfected c-myc genes. C-myc expression in the three nontransfected control cell lines, H209, H 146, and N4 17, and five H209 derived transfected clones differ markedly (Fig. 4) . By Northern blot analysis the parental cell line H209 expresses no detectable c-myc mRNA. In contrast, N4 17 is amplified for c-myc and produces abundant mRNA. Cell line H 146 is not amplified for c-myc but makes significant levels of c-myc mRNA (Fig. 4) . Dilution experiments demonstrate H209 is expressing <1/20 of the mRNA produced by H 146 (data not shown). Transfected clones A, B, C, and E all contain exogenous c-myc DNA and all make normal size c-myc mRNA (2.3 kb). Clone E produces more mRNA than clone A and B while clone C produces the least. In contrast, clone D, which contains no exogenous c-myc DNA, makes no detectable c-myc mRNA (Fig. 4) .
The human c-myc gene uses two different promoters in the first exon separated by 170 bp (25) . The more 5' of these is designated PI and the more 3' is designated P2. We therefore (Table  I ). The c-myc mRNA signal on autoradiographs was quantitated by densitometry and the amount of c-myc mRNA in each lane was standardized using a beta actin mRNA signal as a reference control. The cell growth curves of the c-myc transfected clones grew more rapidly than the parent line, H209 (Table I ). Clones A, B, C, and E all grew faster than the parent line, H209. Clone D, the clone with no transfected c-myc, grew at a rate comparable to the original cell line, H209. Most significantly, on doubling time replicates performed 1 mo apart, clone D, with no detectable c-myc mRNA, maintains a mean doubling time similar to the parent cell line H209 (90 vs. 94 h). In clones A, B, and E the mean doubling time decreases to 54, 51, and 57 h, respectively. The clone which expresses the least c-myc mRNA, clone C, also has the longest mean doubling time, 62 h. However, the doubling times do not decrease to the time seen in the c-myc amplified variant cell line, N417 (33 h).
The cloning efficiency of H209 is also increased after transfection and expression of c-myc. Clone E, the highest c-myc H209 CLONE E H209 N417
5 $VO in clone A and the doubling time was shortened, no difference in the cloning efficiency was observed compared with the parental line H209. Possible explanations are that an early observed effect with increased c-myc mRNA is more rapid growth, but a higher level ofc-myc mRNA expression is needed to observe an increase in cloning efficiency, or additional unidentified factors other than c-myc are present in H 146 which increase the cloning efficiency.
Biochemical properties. The parent line, H209, produces large amounts ofbombesin-like immunoreactivity (Table I) . Both c-myc producing control SCLC lines, H146 and N417, yield very low levels of bombesin-like immunoreactivity (gastrin releasing peptide). Bombesin is produced in all five transfected clones at levels comparable to or greater than the parent cell line H209. L dopa decarboxylase, a marker of neuroendocrine differentiation, is produced in the control cell lines, H209 and H 146, but not in the variant, N4 17 (Table I ). L dopa decarboxylase continued to be produced in all five transfected clones.
Discussion
The small cell lung cancer system offers an opportunity for studying the role ofc-myc in human malignancy. We have demonstrated that electroporation can introduce an exogenous normal human c-myc gene into a typical classic SCLC cell line, H209, and that c-myc mRNA can now be expressed. The clone producing the highest amount of steady state c-myc mRNA, clone E, shows properties analogous to the variant type ofSCLC associated with c-myc amplification and expression (15) . The morphology in cell culture became more open and linear, the atymic nude mice xenotransplants developed larger cells with prominent nucleoli, the doubling time shortened, and the cloning efficiency increased. However, the bombesin-like immunoreactivity and L dopa decarboxylase production did not markedly decrease.
Classic SCLC cells are unusual because the cell lines examined with the exception of H146 have no detectable c-myc mRNA expression (11, 12 (Fig. 2, first panel) . However, the 8.8-kb Hind III fragment derived from the construct remains intact in all the clones except for the single band from clone E. (Fig. 2, second panel) . It is interesting to observe that all the areas of the human c-myc locus which cross-hybridize with the mouse c-myc locus are contained in this Hind III-Eco RI fragment (25) . The deletion of the most 5' sequences of the 12.7 kb Eco RI c-myc fragment and the loss ofthe coding exons of c-myc in clone E suggest that the c-myc gene may be altered during electroporation; during integration into the host genome, or may be deleted after integration.
The SI nuclease analysis also shows that the promoter utilization of the c-myc gene in SCLC can be altered after transfection. In the SCLC cell lines producing c-myc mRNA, the 1:3 PI/P2 promoter ratio seen in Epstein-Barr Virus transformed lymphocytes is maintained (12, 33) . In the transfected cell line clone E switches to make PI the predominant promoter. This is analogous to the Burkitt's lymphoma cell lines, BL16, BL22, BL3 1, and BL37, where all three coding exons of c-myc remain together after rearrangement and the PI/P2 ratio changes to approximately equimolar (33, 34). Thus, in both these systems when all three exons of c-myc are introduced into a new chromosomal environment, the promoter ratio is changed despite the three-exon structure of the gene remaining intact.
Morphologic changes and alterations in growth properties with myc transfection have been observed in 'other systems. NIH/ 3T3, Rat-2 (3), and avian embryonic fibroblasts (35) change morphology after transfection with c-myc or v-myc. In addition, more 'rapid growth in low serum and higher cloning efficiencies are seen with rat-2 and NIH/3T3 cells after transfection with cmyc (3). Variant SCLC cell lines have markedly decreased or absent bombesin-like immunoreactivity and have decreased production of one of the neuroendocrine markers, L dopa decarboxylase. At the level of c-myc expression in the transfected clones, the biochemical markers, bombesin-like immunoreactivity and Ldopa decarboxylase, are not markedly different from those of the original clone. The steady state level of c-myc mRNA in the transfectants is at least 10-fold below the variant N417. This may explain the observation that the L dopa decarboxylase activity does not decrease to the level of the variant, N4 17 (Table  I) , if high levels of c-myc mRNA are needed to suppress L dopa decarboxylase activity. However, some of the transfectants produce steady state c-myc mRNA comparable to the control cell line H 146 where bombesin-like immunoreactivity is decreased (Table I ). Eight additional clones were examined for bombesinlike immunoreactivity and none were markedly decreased (data not shown). It is possible that the altered growth properties and morphology may be associated with c-myc mRNA production and the biochemical properties are independent but at this time there is insufficient data to draw any firm conclusions.
This study shows that following transfection of the c-myc gene in a c-myc-neo construct into a parent SCLC cell line, H209, not expressing c-myc mRNA results in c-myc mRNA expression. This expression is associated with the altered cellular morphology, accelerated growth rates, and increased cloning efficiencies also observed in SCLC cell lines naturally expressing c-myc mRNA. These observations demonstrate that increased c-myc expression can cause altered growth properties and altered morphology in human SCLC.
